Neola Medical AB (NEOLA) Fair Value & Analysis
Healthcare · SE · Market cap 54.9M SEK
Fair value as of: Jul 16, 2026
From 1 valuation models · updated today
Fair value updated Jul 16, 2026, revised from kr 4.23 to kr 0.1800 (−95.7%) since Jun 24, 2026. Share price −24.7% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 0.6400 – kr 2.39 · fair‑value band kr 0.1200 – kr 0.2200 · the kr 0.7000 price screens above the kr 0.1800 fair value. As of Jul 16, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Neola Medical AB (NEOLA) currently trades at kr 0.7000, while our model-based Fair Value estimate is kr 0.1800, implying the stock looks roughly 74.3% overvalued today. We read business quality at 27/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 9.0M SEK. Revenue grew 32.6% year over year. It earns a return on equity of -15.3%. The balance sheet holds a net cash position of 16.1M SEK. Fundamentals as of Jul 16, 2026
Our scenario range runs from kr 0.1200 (bear case) to kr 0.2200 (bull case); at kr 0.7000, the current price sits above that range. The share trades about 77% below its 52-week high and 16% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -29% fair-value upside, at -74%, NEOLA screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 16, 2026. TTM = trailing twelve months.
About the company
Neola Medical AB (publ), together with its subsidiary, Neola Medical, Inc., develops medical technology devices for non-invasive continuous monitoring of the lungs of preterm born infants in Sweden. It offers NEOLA, a neonatal intensive care medical device that enables continuous lung monitoring and real-time alerts of life-threatening complications using technology that measures lung volume changes and oxygen gas concentration. The company was formerly known as GPX Medical AB and changed its name to Neola Medical AB (publ) in June 2022. Neola Medical AB (publ) was incorporated in 2016 and is headquartered in Lund, Sweden.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Neola Medical AB reported revenue of kr 0 in FY2025 versus kr 625K in FY2021. Reported net income was −kr 11.0M in FY2025.
Is NEOLA fairly valued? → Check now
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABL | €78.04 | €61.19 | -22% |
| Stryker Corporation SYK | $305.66 | $187.83 | -39% |
| Medtronic plc MDTC34 | R$211.05 | R$29.52 | -86% |
| Boston Scientific Corporation B1SX34 | R$247.01 | R$234.82 | -5% |
| Edwards Lifesciences Corporation EWL | €74.64 | €31.98 | -57% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
| DexCom, Inc DXCM | $72.59 | $39.33 | -46% |
| GE HealthCare Technologies Inc GEHC | $63.76 | $44.97 | -29% |
| Koninklijke Philips N.V 1PHIA | €24.31 | €9.97 | -59% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥144.39 | ¥105.08 | -27% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Neola Medical AB (NEOLA) undervalued?
What is the fair value of NEOLA?
What is the quality score of NEOLA?
What is the revenue of Neola Medical AB (NEOLA)?
What is the net profit margin of NEOLA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Neola Medical AB analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.